Hyloris Pharmaceuticals SA (52U) Stock Statistics & Valuation Metrics

Hyloris Pharmaceuticals SA has a market cap or net worth of €162.40M. The enterprise value is €272.94M.

Hyloris Pharmaceuticals SA has 28,000,374 shares outstanding. The number of shares has decreased by -2.65% in one year.

Hyloris Pharmaceuticals SA’s return on equity (ROE) is -0.20 and return on invested capital (ROIC) is -20.40%.

The current PE Ratio of Hyloris Pharmaceuticals SA is -29.95. Hyloris Pharmaceuticals SA’s PEG ratio is 2.64.

In the last 12 months, Hyloris Pharmaceuticals SA had revenue of 10.04M and earned -6.34M in profits. Earnings per share was -0.22.

In the last 12 months, operating cash flow was -6.70M and capital expenditures -29.00K, giving a free cash flow of -6.73M billion.

Hyloris Pharmaceuticals SA pays an annual dividend of ―, resulting in a dividend yield of ―

Hyloris Pharmaceuticals SA upcoming earnings date is Sep 25, 2025, TBA Not Confirmed.

Hyloris Pharmaceuticals SA as a current ratio of 4.15, with Debt / Equity ratio of 1.61%

In the past 12 months, Hyloris Pharmaceuticals SA has paid -81.00K in taxes.

Hyloris Pharmaceuticals SA EV to EBITDA ratio is -34.69, with an EV/FCF ratio of -24.98.

Hyloris Pharmaceuticals SA has €24.15M in cash and marketable securities with €1.81M in debt, giving a net cash position of -€22.34M billion.

Gross margin is 96.81%, with operating margin of -71.00%, and net profit margin of -63.15%.

The average price target for Hyloris Pharmaceuticals SA is €16.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy